December 23, 2025—Edwards Lifesciences announced FDA approval for the company’s Sapien M3 transcatheter mitral valve replacement (TMVR) sy

October 31, 2025—Egg Medical, Inc. announced the presentation of real-world studies demonstrating that the company’s EggNest Complete radi

October 29, 2025—The Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal de

October 27, 2025—Penumbra, Inc. announced that the results of the STORM-PE randomized controlled trial showed that mechanical thrombectomy using

September 18, 2025—Imperative Care, Inc. announced efficacy and safety results from the pivotal SYMPHONY-PE trial. The prospective, multicenter

September 3, 2025—Laza Medical, Inc., which is developing artificial intelligence (AI)–powered robotic ultrasound image guidance technolog

September 2, 2025—Imperative Care, Inc. announced it has received FDA 510(k) clearance of its Symphony thrombectomy system to treat pulmonary em

August 25, 2025—Artrya Limited announced it has received 510(k) clearance from the FDA for the Salix coronary plaque module. The module is part

August 25, 2025—The FDA announced it has commenced daily publication of adverse event data from the FDA Adverse Event Reporting System (FAERS).

August 25, 2025—Otsuka Medical Devices Co., Ltd. announced that the Paradise ultrasound renal denervation (uRDN) system has received manufacturi

August 11, 2025—Gentuity LLC, a developer of intravascular imaging devices, recently announced an agreement with GE HealthCare to collaborate on

Babar Basir, DO, FACC, FSCAI, shares insights into the development and growth of the NCSI, discussing its impact on cardiogenic shock care over the past 10 years, as well as future endeavors.

SCAI President Srihari S. Naidu, MD, is challenging the interventional cardiology field and all members of the shock team to achieve a door-to-lactate clearance of 24 hours to improve cardiogenic shoc...

July 17, 2025—Biosensors International recently announced it received CE Mark certification for the Imperia delivery system under the European U

July 11, 2025—The United States Centers for Medicare & Medicaid Services (CMS) recently announced it has issued a National Coverage Determin

July 7, 2025—Medtronic announced that the first patient has been treated in its SPYRAL GEMINI global pilot study, which will investigate the saf

July 2, 2025—MiRus, LLC, announced the presentation of 30-day results from the United States early feasibility study (EFS) of the company’

June 27, 2025—Foldax Inc., a Utah-based developer of polymer heart valves, announced 1-year results from a clinical trial in India of the compan

June 24, 2025—Edwards Lifesciences Corporation announced that the company’s Evoque tricuspid valve replacement system has received Health

As interventional cardiologists, we are tasked with providing the best care to our patients, oftentimes while putting our own health and safety at

A discussion of first steps, getting buy-in from administration and colleagues, essential support staff and service lines, building and maintaining relationships, obtaining referrals, raising awarenes...

June 10, 2025—The American College of Cardiology (ACC) reported that the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Isra

June 9, 2025—Jenscare Scientific Co., Ltd. recently announced that 1-year outcomes from a study of the JensClip transcatheter mitral valve repla

The next decade of cardio-oncology is likely to include an increased presence in training programs, more outcomes data for intervention in specific cardiovascular presentations, improved patient quali...

The role of the interventional cardiologist, building a practice, and the future of the subspecialty.

Leading experts in cardio-oncology discuss where the interventional cardiologist fits in the cardio-oncology field, challenges to treating cancer patients in the cath lab, treatment considerations for...

News and information on minimally invasive coronary disease therapies, covering valvular, structural, radial access, chronic total occlusion, and imaging issues.

May 27, 2025—Abbott announced FDA approval of the company’s Tendyne transcatheter mitral valve replacement (TMVR) system for the treatment

Challenges with nondedicated and dedicated devices, uncertain predictors, and long-term implications.

May 20, 2025—Shockwave Medical, Inc., part of Johnson & Johnson MedTech, announced the 30-day primary endpoint results of the EMPOWER CAD st

Challenges of TAVR in the treatment of pure aortic regurgitation and how dedicated devices can overcome them.

In This Issue Matti Adam, MD, and Jonathan Curio, MD, introduce our latest issue focusing on emerging and future technologies for treating aortic regurgitation. Plus: pulmonary embolism in practice.

May 13, 2025—GE HealthCare announced that the FDA has approved a pediatric indication for the company’s Optison (perflutren protein-type A

Prof. Mahfoud breaks down his translational cardiology research focused on the autonomic nervous system and interorgan communication in cardiovascular disease, remaining hurdles and research prioritie...

In a cohort of patients with asymptomatic, severe aortic stenosis (AS), Généreux et al found that early transcatheter aortic valve repla

May 7, 2025—FastWave Medical announced it has received institutional review board (IRB) approval to commence a coronary feasibility study using

May 2, 2025—Society for Cardiovascular Angiography & Interventions (SCAI) announced that an analysis from the EARLY TAVR trial showed patien

May 1, 2025—The Society for Cardiovascular Angiography & Interventions (SCAI) announced the presentation of data demonstrating that women ar

May 1, 2025—The Society for Cardiovascular Angiography & Interventions (SCAI) announced findings from a study demonstrating that stenting im

April 29, 2025—Orchestra BioMed Holdings, Inc. announced that the FDA has approved an investigational device exemption (IDE) amendment to initia

A discussion of echocardiographic assessment combined with cardiac MR and CT for comprehensive aortic regurgitation evaluation.

April 28, 2025—Transverse Medical Inc. announced the completion of a Series B2 financing round of more than $10 million. The Colorado-based earl

April 27, 2025—Abbott announced late-breaking data from the AVEIR conduction system pacing (CSP) acute clinical feasibility study, which demonst

April 28, 2025—Rampart IC, a developer of radiation shielding for interventional suites, announced the acquisition of ClearShield, manufacturer

What (and who) to always have ready.

Epidemiologic trends, current guidelines, and future directions.

Aortic regurgitation (AR) remains underdiagnosed, and many patients may still be treated too late. However, in recent years, it has gained increa

April 16, 2025—Luma Vision Ltd., an Ireland- and Germany-based developer of cardiac imaging and navigation technology, announced the FDA clearan

April 17, 2025—Adagio Medical Holdings, Inc. announced that it has received FDA Breakthrough Device designation for its vCLAS cryoablation syste